# Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

Source: https://onco.cc/trials/nct06566079/  
OnCo record `nct06566079` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ISM6331 in mesothelioma, run by InSilico Medicine Hong Kong Limited, now recruiting.

## Summary

Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06566079 by InSilico Medicine Hong Kong Limited, with 160 participants planned, started 2024-12-27 and due to reach its primary completion in 2027-08-31. Interventions recorded: ISM6331.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06566079
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
- Sponsor: InSilico Medicine Hong Kong Limited
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT06566079: https://clinicaltrials.gov/study/NCT06566079

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/)

---
JSON: https://onco.cc/api/v1/entities/nct06566079.json